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Clopidogrel responsiveness in chronic kidney disease patients with acute coronary 
syndrome
Akut koroner sendromlu kronik böbrek hastalarında klopidogrel cevabı
Hale Ünal Aksu1, Hüseyin Aksu1, Ender Öner1, Nilgün Işıksaçan2, Ömer Çelik1, Mehmet Ertürk1, 
Ali Kemal Kalkan1, Muhammed Hulusi Satılmışoğlu1
ÖZET
Amaç:  Kardiyovasküler  hastalıklar,  kronik  böbrek  has-
talığı (KBH) olanlarda önde gelen ölüm sebebidir. KBH’ 
nın klopidogrel cevabı üzerine olan etkisi hakkında çeliş-
kili kanıtlar vardır. Bu çalışmada, akut koroner sendromlu 
kronik böbrek hastalarında klopidogrel yanıtını değerlen-
dirmeyi amaçladık.
Yöntemler: Akut koroner sendrom ile hospitalize edilen; 
orta ileri KBH olan 55, normal böbrek fonksiyonu olan 
veya hafif KBH bulunan 46; toplamda 101 hasta çalışma-
ya dahil edildi. Klopidogrel yanıtını değerlendirmek için 
Multiplate testi kullanıldı. Trombosit agregasyon sonuçları 
agregasyon birimi (AU)*dak olarak verildi ve 470 AU*dak 
üzerindeki değerler klopidogrele düşük cevaplılar olarak 
kabul edildi.
Bulgular:  Çalışmaya  dahil  edilen  101  hasta  (ortalama 
yaş 64.76±8.67, 61 [60.4%]’ i erkek) şu şekilde iki çalış-
ma  grubuna  ayrıldı:  grup  1;  eGFH<60  ml/dak/1.73  m2 
olan 55 hasta, grup 2; eGFH>60 ml/dak/1.73 m2 olan 46 
hasta.  Çalışma  populasyonundaki  35  hastada  (34.7%) 
klopidogrele düşük yanıt bulundu (grup 1’den 16 [34.8%] 
hasta; grup 2’den 18 [33.3%] hasta, p=0.879). Multipla-
te test sonuçları açısından grup 1 ve 2 arasında anlamlı 
fark  yoktu  (414.67±281.21  vs  421.56±316.19  AU*dak, 
p=0.909).  Klopidogrele  düşük  yanıt,  aspirin  cevabının 
Multiplate test sonuçları ile (odds ratio [OR]=1.004, confi-
dence interval [CI] 1.002–1.007, p=0.001) ve hemoglobin 
ile (OR=0.727, CI 0.571–0.925, p=0.010) bağımsız olarak 
ilişkili idi. Yine Multiplate sonuçları; aspirin yanıtının Mul-
tiplate test sonuçları (β=0.402, p<0.0001) ve hemoglobin 
(β=-0.251, p=0.007) ile bağımsız olarak ilişkili idi. 
Sonuç:  Klopidogrele  trombosit  yanıtı;  eGFH  <  60  ml/
dak/1.73 m2 ve eGFH>60 ml/dak/1.73 m2 olan hastalar 
arasında değişmiyor.
Anahtar kelimeler: Akut koroner sendrom , kronik böb-
rek hastalığı, klopidogrel cevabı
ABSTRACT
Objective:  Cardiovascular  diseases  are  the  leading 
cause of death in patients with chronic kidney disease 
(CKD). There is conflicting evidence about effect of CKD 
on clopidogrel responsiveness. We aimed to evaluate the 
clopidogrel responsiveness in CKD patients with acute 
coronary syndrome (ACS).
Methods: A total of 101 patients; 55 with moderate to 
severe CKD and 46 with normal renal function or mild 
CKD, hospitalized with ACS were included in our study. 
Multiplate test was used to determine clopidogrel respon-
siveness. Platelet aggregation results were presented as 
aggregation unit (AU)*min and values over 470 AU*min 
were accepted as clopidogrel low responders. 
Results: The 101 patients (mean age 64.76±8.67 years; 
61  [60.4%]  male)  were  grouped  into  the  two  study 
groups as follows: group 1; 55 patients with eGFR<60 
ml/min/1.73 m2 and group 2; 46 patients with eGFR>60 
ml/min/1.73 m2. 35 patients (34.7%) of the study popu-
lation  were  found  to  have  low  response  to  clopidogrel 
(16 [34.8%] patients in group 1 and 18 [33.3%] patients 
in  group  2,  p=0.879)  . There  was  no  significant  differ-
ence between group 1 and 2 for Multiplate test results 
(414.67±281.21  vs  421.56±316.19  AU*min,  p=0.909). 
Clopidogrel low responsiveness were independently re-
lated to Multiplate test results of aspirin responsiveness 
(OR=1.004, CI 1.002–1.007, p=0.001) and hemoglobin 
(OR=0.727, CI 0.571–0.925, p=0.010). Multiplate results 
were also independently related to Multiplate test results 
of aspirin responsiveness (β=0.402, p<0.0001) and he-
moglobin (β=-0.251, p=0.007). 
Conclusion: Platelet response to clopidogrel does not 
differ between patients with eGFR < 60 ml/min/1.73 m2 
and eGFR>60 ml/min/1.73 m2.
Key words: Acute  coronary  syndrome,  chronic  kidney 
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INTRODUCTION
Clopidogrel is a thienopyridine that irreversibly in-
hibits platelet adenosine diphosphate P2Y12 recep-
tor, which is a key signaling pathway of the platelet 
activation. Clopidogrel is widely used in patients 
with coronary artery disease. Dual antiplatelet treat-
ment is the standard therapy for patients after acute 
coronary syndromes (ACS) and undergoing percu-
taneous  coronary  interventions  (PCI).  Guidelines 
recommend 1 year dual antiplatelet treatment in pa-
tients with ACS [1].
Interindividual variability of response to clopi-
dogrel therapy has been demonstrated in some stud-
ies  [2].  The  clinical  importance  of  this  situation 
has been demonstrated in different clinical condi-
tions such as ACS and after PCI [3-5]. Although 
clopidogrel resistance is used in clinical practice; in 
fact it is a low responsiveness to clopidogrel. It is 
a multifactorial phenomenon. Variability of plate-
let response to clopidogrel is likely to develop as 
a result of a decreased bioavailability of the active 
metabolite, due to genetic variation or concomitant 
drug treatment [2].
Cardiovascular diseases are the leading cause 
of  death  in  patients  with  chronic  kidney  disease 
(CKD). Patients with all stages of CKD experience 
higher rates of atherothrombotic disease manifes-
tations than the general population [6-8]. This un-
derlies the importance of antithrombotic therapy in 
these patients. There is conflicting evidence about 
effect of CKD on clopidogrel responsiveness. Some 
studies  demonstrated  high  rates  of  clopidogrel 
low responsiveness (CLR) in CKD patients [9,10] 
whereas  someother  did  not  showed  any  relation 
[11]. 
The aim of our study was to evaluate the clopi-
dogrel responsiveness in CKD patients with ACS.
METHODS
This study was approved by the local ethics com-
mittee, and all participants gave written informed 
consent before participating. 
Estimated  glomerular  filtration  rate  (eGFR) 
of 312 consecutive patients hospitalized with ACS 
was calculated by using the Modification of Diet in 
Renal Disease Study Formula [12]. 46 of these pa-
tients with normal renal function or mild CKD and 
55 with moderate to severe CKD, total 101 patients 
were included in the study. We classified the 101 pa-
tients into two study groups according to their eGFR 
values. Group 1 included 55 patients with moder-
ate  to  severe  CKD  (eGFR<  60  ml/min/1.73  m2) 
and group 2 included 46 patients with mild CKD 
or normal renal function (eGFR> 60 ml/min/1.73 
m2). Aspirin and clopidogrel responsiveness were 
assessed after 7 days of regular 100 mg acetyl sali-
cylic acid (ASA) and clopidogrel 75 mg once a day 
prescription. The discharged patients during this pe-
riod were called for the test and their drug compli-
ance were determined by patient interviews.
Patients  taking  an  antiplatelet  therapy  other 
than ASA and clopidogrel (ticlopidine, dipyridam-
ole,  nonsteroidal  anti-inflammatory  drugs,  pent-
oxyphillin, cilostazol), previous treatment with gly-
coprotein IIb/IIIa inhibitors within 10 days, active 
malignancy,  hemorrhagic  diathesis,  thrombolytic 
treatment within the last month, liver disease, plate-
let  counts  <100,000/ml,  and  noncompliant  with 
medical therapy were not included in the study. 
Information on diabetes, hypertension, hyper-
lipidemia, smoking, and medication history of the 
patients were recorded. Fasting blood samples were 
obtained to determine creatinine, blood urea nitro-
gen (BUN), uric acid, blood glucose, lipid profile, 
hemoglobin, mean platelet volume (MPV), leuco-
cyte, and platelet count. We used the multiplate test 
(Dynabyte  Medical,  Munich,  Germany)  to  deter-
mine clopidogrel responsiveness.
Assessment of clopidogrel responsiveness 
Whole blood was obtained via standard venipunc-
ture  at  an  antecubital  vein.  Blood  was  collected 
in tubes containing the anticoagulant hirudin. The 
ADP-induced platelet aggregation in whole blood 
was assessed with multiple electrode aggregometry 
using an impedance aggregometer called Multiplate 
analyzer within two hours of sampling after two to 
four hours of drug ingestion. Details of this method 
have been reported previously [13]. In brief, after 
1:1 dilution of whole blood with 0.9% NaCl solu-
tion and stirring for 3 min in the test cuvettes at 
37°C, 6.4 µmol/l ADP was added. Platelet aggrega-
tion was continuously recorded for 5 min. Imped-
ance with Multipl electrode aggregometry is trans-
formed to arbitrary aggregation units (AU) that are 
plotted against time (AU*min). Aggregation mea-H. Ü. Aksu et al. Clopidogrel responsiveness in patients with chronic kidney disease 36
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sured is quantified as AU and area under the curve 
of arbitrary units (AU*min) and values over 470 
AU*min were accepted as CLR.
Assessment of aspirin responsiveness
Whole blood aggregation was performed with the 
multiplate  analyzer,  an  impedance  aggregometer 
that is based on the principle that activated platelets 
expose receptors on their surface that allow them to 
attach to artificial surfaces. After two to four hours 
of aspirin ingestion, whole blood samples were col-
lected in test tubes containing hirudin (25 mcg/ml) 
as anticoagulant. Arachidonic acid was used as the 
aggregation agonist, and all samples were analyzed 
within 2 hours of collection. The aggregation mea-
sured with this device is quantified as area under 
the curve, aggregation degree, and aggregation ve-
locity. Platelet aggregation results were presented 
as aggregation unit (AU)*min, and values over 500 
AU*min were accepted as aspirin resistance (AR) 
[14]. 
Statistical analysis
Continuous  variables  were  presented  as  mean  ± 
standard  deviation.  Categorical  variables  were 
presented as frequencies and percentages. The un-
paired Student’s t-test for continuous variables and 
χ2-test for categorical variables was performed to 
compare the study groups in relation to eGFR levels 
and patients groups with and without CLR. Correla-
tions between the multiplate test results and CLR 
status with other parameters were analyzed using 
Spearman’s or Pearson’s correlation analysis. Mul-
tivariate associations of the multiplate test results 
were determined by using multiple stepwise linear 
regression analysis with parameters having signifi-
cant correlations in the univariate analysis. For the 
determination  of  the  influential  factors  on  CLR, 
multivariate  logistic  regression  analysis  was  also 
performed on variables with a p value of <0.05 de-
rived from the univariate analysis. The receiver-op-
erating characteristics (ROC) curve was used to test 
the predictive accuracy of eGFR with respect to the 
presence of CLR based on Multiplate test results. 
Significant prediction was accepted when the area 
under  the  ROC  curve  was  significantly  different 
from 0.5. p<0.05 was accepted as statistically sig-
nificant. All analyses were performed using SPSS 
15.0 statistical software.
RESULTS
The 101 patients (mean age 64.76±8.67 years; 61 
[60.4%] male) included in the study were grouped 
into the two study groups as follows: group 1; 55 
patients with eGFR<60 ml/min/1.73 m2, and group 
2;  46  patients  with  eGFR>60  ml/min/1.73  m2. 
Group 1 were included 47 patients with an eGFR 
between 30 and 59 ml/min/1.73 m2 (Stage 3 CRF) 
and 8 patients with eGFR between 15 and 29 ml/
min/1.73 m2 (Stage 4 CRF). Group 2 were includ-
ed 21 patients with an eGFR >90 ml/min/1.73 m2 
without renal disease history and 25 patients with 
an eGFR between 60 and 89 ml/min/1.73 m2 (Stage 
2 CRF). Demographic and clinical features of these 
two groups are listed in Table 1. 
35  patients  (34.7%)  of  the  study  popula-
tion were found to have CLR (aggregation >470 
AU*min). Multiplate test results and CLR status of 
the study groups were also shown in Table 1 and 
Figure-1.
Figure1. Multiplate test results and aspirin resistance ra-
tios in the study groups
The mean value of the multiplate test results 
was 760.05±240.74 (range 475–1232) AU*min in 
the 35 patients with CLR and 238.61±102.13 (range 
25–459) AU*min in the 66 patients with normal 
clopidogrel  response.  Demographic  and  clinical 
features of clopidogrel low responders and clopido-
grel sensitive patients are presented in Table 1.H. Ü. Aksu et al. Clopidogrel responsiveness in patients with chronic kidney disease 37
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Group I 
(n=55)
Group II 
(n= 46) p value
Age, years 67.83 ± 8.29 61.08 ± 7.71 <0.0001
Male, n (%) 27 (49.1) 34 (73.9) 0.011
Hypertension, n (%) 49 (89.1) 30 (65.2) 0.004
Diabetes mellitus, n (%) 32 (58.2) 11 (23.9) 0.001
Hypercholesterolemia, n (%) 45 (81.8) 34 (73.9) 0.338
Smoking, n (%) 13 (23.9) 22 (47.8) 0.011
Body mass index, kg/m2 29.13 ± 4.39 29.02 ± 5.73 0.418
Medication
β-blockers, n (%) 43 (78.2) 39 (84.8.6) 0.398
RAS blockers, n (%) 44 (80.0) 34 (73.9) 0.468
Calcium antagonists, n (%) 18 (32.7) 10 (21.7) 0.219
Statins, n (%) 47 (85.5) 37 (80.4) 0.502
Diuretics, n (%) 11 (20.0) 8 (17.4) 0.738
Laboratory values
Creatinine, mg/dL 1.71 ± 0.96 0.92 ± 0.21 <0.0001
BUN, mg/dL 31.98 ± 17.84 17.06 ± 5.72 <0.0001
Glucose, mg/dL 150.31 ± 85.17 135.51 ± 69.33 0.358
Uric acid, mg/dL 7.15 ± 1.81 5.81 ± 1.69 <0.0001
Total cholesterol, mg/dL 177.34 ± 56.76 161.04 ± 44.72 0.119
LDL, mg/dL 106.74 ± 46.54 95.65 ± 36.55 0.194
HDL, mg/dL 42.82 ± 11.10 40.67 ± 10.97 0.333
Triglyceride, mg/dL 172.83 ± 93.61 161.56 ± 86.22 0.535
WBC, × 103/µl  8.37 ± 3.14 7.74 ± 2.83 0.293
Hemoglobin, g/dL 11.60 ± 1.84 13.43 ± 1.59 <0.0001
Platelet count , × 103/µl 239.31 ± 62.69 238.46 ± 60.45 0.945
MPV, fL 8.45 ± 1.01 8.37 ± 1.59 0.667
Aspirin Response 
Multiplate, AU*min 242.31 ± 262.87 251.95 ± 233.72 0.847
AR, n (%) 7 (12.7) 6 (13.0) 0.962
Clopidogrel response
Multiplate, AU*min 423.18 ± 313.48 414.67 ± 281.21 0.887
CLR, n (%) 19 (34.5) 16 (34.8) 0.980
Both AR and CLR, n (%) 4 (7.3) 5 (10.9) 0.728
CKD, chronic kidney disease; eGFR, estimated Glomerular filtration rate; RAS, 
renin–angiotensin system; BUN, blood urea nitrogen; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein; WBC, white blood cell; MPV, mean platelet 
volume; AR, aspirin resistance.
Table 1.  Demographic  Character-
istics and Laboratory Values of the 
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CLR status was weakly correlated with hemo-
globin (r=–0.201, p=0.044), platelet count (r=0.283, 
p=0.004), LDL (r=0.207, p=0.039), total cholesterol 
(r=0.211, p=0.027), AR status (r=0.279, p=0.005) 
and Multiplate test results of aspirin responsiveness 
(r=0.303, p=0.002). When these parameters which 
had  significant  correlation  with  CLR  status  were 
included in the multivariate analysis, CLR status 
was independently related to Multiplate test results 
of aspirin responsiveness (odds ratio [OR]=1.004, 
confidence interval [CI] 1.002–1.007, p=0.001) and 
hemoglobin (OR=0.727, CI 0.571–0.925, p=0.010). 
Multiplate  test  results  of  clopidogrel  responsive-
ness  were  also  weakly  correlated  with  sex  (r=-
0.223, p=0.025) , hemoglobin (r=-0.233, p=0.019) 
, platelet count (r=0.377, p<0.0001), LDL (r=0.223, 
p=0.026), total cholesterol (r=0.227, p=0.013), AR 
status  (r=0.273,  p=0.006)  and  Multiplate  test  re-
sults of aspirin responsiveness (r=0.340, p=0.001). 
When these parameters which had significant cor-
relation with Multiplate test results were included in 
the multivariate analysis, Multiplate test results of 
clopidogrel responsiveness were also independently 
related to Multiplate test results of aspirin respon-
siveness (β=0.402, p<0.0001) and hemoglobin (β=-
0.251, p=0.007). 
GFR  were  not  correlated  with  CLR  status 
(r=–0.127, p=0.207) and also showed no significant 
discriminatory  capacity  between  clopidogrel  low 
responder and clopidogrel sensitive patients, having 
an area under the ROC curve of 0.577 (CI 0.458-
0.695), p=0.205 (Figure 2).
Figure 2. The receiver-operating characteristics (ROC) 
curve of the estimated glomerular filtration rate (eGFR) 
for detecting clopidogrel low responsiveness (an area un-
der the ROC curve of 0.577 (CI 0.458-0.695), p=0.205)
DISCUSSION
In the present study, we did not observe any sig-
nificant  differences  of  clopidogrel  responsiveness 
between the patients with normal renal function or 
mild CKD (eGFR > 60 ml/min/1.73 m2) and moder-
ate to severe CKD and not on chronic hemodialysis 
treatment. CLR was independently related to only 
Multiplate  test  results  of  aspirin  responsiveness 
and hemoglobin. eGFR was not related to CLR and 
could not predict it. 
In  large  randomized  controlled  trials,  CKD 
has been linked with a lower efficacy of clopido-
grel [15] and there are papers with different results 
about effects of CKD on clopidogrel responsive-
ness. Park et al [10) reported that platelet respon-
siveness to clopidogrel decreased more in patients 
with CKD than in those with normal renal function 
and this decreased response was not improved by 
increased dosage. They included severe CKD pa-
tients (patients had CKD for > 6 months and with 
a serum creatinine concentration > 3 mg/dl) in their 
CKD group and the sample size of the study was 
smaller. Their study included both patients with sta-
ble angina pectoris and unstable angina pectoris in 
contrast to our study group with ACS. Clopidogrel 
responsiveness was also determined by VerifyNow, 
not Multiplate method. Angiolillo et al showed im-
paired renal function was associated with reduced 
clopidogrel-induced antiplatelet effects in diabetic 
patients with coronary artery disease taking main-
tenance aspirin and clopidogrel therapy. Their study 
group was only diabetics and clopidogrel respon-
siveness  was  assessed  by  light  transmittance  ag-
gregometry method.
Like our study results; Cuiset et al also did not 
find any significant effect of CKD on clopidogrel 
responsiveness assessed by PRI VASP, neither for 
acute response, nor for chronic response with high 
dose [11] in the patients with ACS . 
The mechanisms leading to variability in clopi-
dogrel responsiveness are not fully understood, but 
likely to be multifactorial. It is caused by genetic 
and nongenetic causes. Increased baseline platelet 
reactivity; commonly observed in some clinical sce-
narios such as ACS, diabetes mellitus and increased 
body mass index may lead to decreased clopidogrel 
responsiveness. [16-19]. Differences in individual 
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metabolite may also lead to clopidogrel response 
variability [20]. Also drugs that are substrates or in-
hibit the CYP isoenzyme 3A4 can lead to reduced 
antiplatelet effects [21].
Cardiovascular diseases are the leading cause 
of death in patients with CKD. These patients are at 
increased risk for both thrombosis and hemorrhage. 
Morel et al reported low platelet response to clopi-
dogrel was associated with worse outcomes after 
PCI in patients with CKD [22]. Also in their study 
degree of P2Y12 inhibition by clopidogrel was not 
significantly  different  in  the  CKD  and  non-CKD 
groups. Htun et al also demonstrated low response 
to clopidogrel was an additional risk factor for the 
poorer post-PCI outcomes in patients with moder-
ate to severe CKD patients [23]. So it is important 
to highlight if aspirin and clopidogrel responsive-
ness are lower in CKD patients and to decide the 
management  of  this  situation  without  increasing 
hemorrhagic  complications.  As  the  patients  with 
CKD also prone to hemorrhagiac complications it 
is important to avoid high dose of antithrombotic 
treatments without any evidence. 
We did not include patients with end-stage re-
nal disease and on chronic hemodialysis. This is 
the limitation of our study and large studies with 
all stages of CKD patients including hemodialysis 
patients with both predialysis and postdialysis tests 
are needed to clear the relation between CKD and 
antiplatelet responsiveness.
In conclusion, Platelet response to clopidogrel 
does not differ between patients with mild CKD or 
normal renal function and patients with moderate to 
severe CKD. 
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